Iroko is a global specialty pharmaceutical company, based in Philadelphia, dedicated to advancing the science of analgesia. The company develops and globally commercializes pharmaceutical products. In addition to the Iroko products that are marketed worldwide, the company has a robust pipeline of investigational lower dose NSAID products being developed using iCeutica Pty Ltd's proprietary SoluMatrix Fine Particle Technology™.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 11/22/13 | $75,000,000 | Debt Financing |
OrbiMed Advisors | undisclosed |
